321 related articles for article (PubMed ID: 7660122)
1. Inhibition of transcription elongation by the VHL tumor suppressor protein.
Duan DR; Pause A; Burgess WH; Aso T; Chen DY; Garrett KP; Conaway RC; Conaway JW; Linehan WM; Klausner RD
Science; 1995 Sep; 269(5229):1402-6. PubMed ID: 7660122
[TBL] [Abstract][Full Text] [Related]
2. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II.
Aso T; Lane WS; Conaway JW; Conaway RC
Science; 1995 Sep; 269(5229):1439-43. PubMed ID: 7660129
[TBL] [Abstract][Full Text] [Related]
3. Identification of elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein.
Takagi Y; Pause A; Conaway RC; Conaway JW
J Biol Chem; 1997 Oct; 272(43):27444-9. PubMed ID: 9341197
[TBL] [Abstract][Full Text] [Related]
4. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.
Kibel A; Iliopoulos O; DeCaprio JA; Kaelin WG
Science; 1995 Sep; 269(5229):1444-6. PubMed ID: 7660130
[TBL] [Abstract][Full Text] [Related]
5. Characterization of elongin C functional domains required for interaction with elongin B and activation of elongin A.
Takagi Y; Conaway RC; Conaway JW
J Biol Chem; 1996 Oct; 271(41):25562-8. PubMed ID: 8810329
[TBL] [Abstract][Full Text] [Related]
6. The inducible elongin A elongation activation domain: structure, function and interaction with the elongin BC complex.
Aso T; Haque D; Barstead RJ; Conaway RC; Conaway JW
EMBO J; 1996 Oct; 15(20):5557-66. PubMed ID: 8896449
[TBL] [Abstract][Full Text] [Related]
7. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.
Pause A; Lee S; Worrell RA; Chen DY; Burgess WH; Linehan WM; Klausner RD
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2156-61. PubMed ID: 9122164
[TBL] [Abstract][Full Text] [Related]
8. Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC.
Feldman DE; Thulasiraman V; Ferreyra RG; Frydman J
Mol Cell; 1999 Dec; 4(6):1051-61. PubMed ID: 10635329
[TBL] [Abstract][Full Text] [Related]
9. Interaction of von Hippel-Lindau tumor suppressor gene product with elongin.
Pause A; Aso T; Linehan WM; Conaway JW; Conaway RC; Klausner RD
Methods Enzymol; 1996; 274():436-41. PubMed ID: 8902823
[No Abstract] [Full Text] [Related]
10. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
11. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
[TBL] [Abstract][Full Text] [Related]
12. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
13. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis.
Richards FM; Schofield PN; Fleming S; Maher ER
Hum Mol Genet; 1996 May; 5(5):639-44. PubMed ID: 8733131
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product.
Tsuchiya H; Iseda T; Hino O
Cancer Res; 1996 Jul; 56(13):2881-5. PubMed ID: 8674032
[TBL] [Abstract][Full Text] [Related]
15. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma.
Olschwang S; Richard S; Boisson C; Giraud S; Laurent-Puig P; Resche F; Thomas G
Hum Mutat; 1998; 12(6):424-30. PubMed ID: 9829912
[TBL] [Abstract][Full Text] [Related]
16. Binding of elongin A or a von Hippel-Lindau peptide stabilizes the structure of yeast elongin C.
Botuyan MV; Koth CM; Mer G; Chakrabartty A; Conaway JW; Conaway RC; Edwards AM; Arrowsmith CH; Chazin WJ
Proc Natl Acad Sci U S A; 1999 Aug; 96(16):9033-8. PubMed ID: 10430890
[TBL] [Abstract][Full Text] [Related]
17. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
[TBL] [Abstract][Full Text] [Related]
18. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function.
Stebbins CE; Kaelin WG; Pavletich NP
Science; 1999 Apr; 284(5413):455-61. PubMed ID: 10205047
[TBL] [Abstract][Full Text] [Related]
19. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products.
Schoenfeld AR; Davidowitz EJ; Burk RD
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8507-12. PubMed ID: 10900011
[TBL] [Abstract][Full Text] [Related]
20. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.
Ohh M; Takagi Y; Aso T; Stebbins CE; Pavletich NP; Zbar B; Conaway RC; Conaway JW; Kaelin WG
J Clin Invest; 1999 Dec; 104(11):1583-91. PubMed ID: 10587522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
